SCHEMBL2052776

SCHEMBL2052776

Cc1nc2ccc(F)cc2nc1C=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.44
KMT2A Q03164 3/20 0.43
CASP3 P42574 1/20 0.42
TSHR P16473 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
PDE10A Q9Y233 3/20 0.38
PLA2G2A P14555 1/20 0.36
BRD4 O60885 1/20 0.35
ALDH1A1 P00352 2/20 0.35
MPO P05164 2/20 0.35
MAPT P10636 2/20 0.35
TYMS P04818 1/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
MAPK1 P28482 1/20 0.35
CASP1 P29466 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2023290 1.00 KDM4E (0.44) KDM4EKMT2ACASP3TSHRTDP1
SCHEMBL7940423 0.82 NQO2 (0.52) KDM4EKMT2ATDP1ALDH1A1MAPT
SCHEMBL7928982 0.82 NQO2 (0.52) KDM4EKMT2ATDP1ALDH1A1MAPT
SCHEMBL2020017 0.82 ALOX15 (0.33) TDP1BRD4CYP1A2CYP3A4CYP2C19
SCHEMBL7935792 0.81 KDM4E (0.43) KDM4EKMT2ACASP3TSHRTDP1
SCHEMBL12574606 0.81 KDM4E (0.43) KDM4EKMT2ACASP3TSHRTDP1
SCHEMBL12638658 0.81 KDM4E (0.57) KDM4EKMT2ACASP3TSHRTDP1
SCHEMBL7937979 0.79 KDM4E (0.53) KDM4EKMT2AALDH1A1MAPTNPC1
SCHEMBL12638660 0.79 KDM4E (0.53) KDM4EKMT2AALDH1A1MAPTNPC1
SCHEMBL2021348 0.79 NPC1 (0.43) KDM4EKMT2ATSHRTDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350027-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS Mitsubishi Tanabe Pharma Corporation (JP) 2011-08-03 EP disclosed
CN-102143951-A Tri-substituted pyrimidine compounds and their use as PDE10 inhibitors MITSUBISHI TANABE PHARMA CORP 2011-08-03 CN disclosed
US-20110160206-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-06-30 US disclosed
US-20110160206-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-06-30 US disclosed
US-20110160206-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-06-30 US disclosed
WO-2010027097-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-03-11 WO disclosed
WO-2010027097-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160206-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS PDE10A, PDE12, PDE9A KDM4E 322/4885KMT2A 1750/4885CASP3 3549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.